Ravindra Majeti

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Pheast Therapeutics Inc is a pre-clinical stage immuno-oncology company that focuses on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. The company is based in Palo Alto, CA. Pheast aims to develop novel therapies for some of the most difficult-to-treat and aggressive cancers, as well as women's cancers including ovarian cancer and breast cancer. The company was founded in 2020 and is led by scientific experts in innate immunity and cancer immunotherapy. Jacopo Leonardi has been the CEO of the company since 2023.

Orbital Therapeutics, Inc. is a company based in Cambridge, MA that aims to enhance health by utilizing RNA-based medicines to treat human diseases in innovative ways. The company is building a platform that combines RNA technology delivery methods, data science, and automation to develop a portfolio of medicines focused on vaccines, immunomodulation, protein replacement, and regenerative medicine. The company was founded by Drew Weissman, John M. Maraganore, Kristina M. Burow, Ravindra Majeti, Giuseppe Ciaramella, Eugene W. Yeo, Howard Y. Chang, and Carol Suh, with Giuseppe Ciaramella serving as the CEO since incorporation.